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ABSTRACT (structured, 194 words (max 200 words)) 
 
Background 
We aimed to estimate the vaccine efficacy (VEC) and duration of protection of pneumococcal 
conjugate vaccines (PCVs) against S.pneumoniae carriage acquisition, through meta-
regression models. 
 
Methods 
We identified intervention studies providing nasopharyngeal carriage estimates among 
vaccinated and unvaccinated children at any time after completion of the vaccination 
schedule. We calculated VEC   for  PCV7 serotypes, grouped as well as individually,  and 
explored cross protective serotypes 6A and 19A using a Bayesian meta-logistic regression 
approach, with time since vaccination as a covariate.  
 
Results  
We used data from 22 carriage surveys (15 independent studies) from 5 to 64 months after 
the last PCV dose, including 14,298 children. The aggregate VEC for all 7 serotypes 6 
months after the last dose of a full schedule was 58% (95%CrI 50 – 65%), varying by 
serotype from 38% (19F) to 80% (9V). We found evidence of sustained protection through 
PCVs for several years, with an aggregate VEC of 40% at 5 years, with VEc waning 
differently between serotypes. 
 
Conclusion 
Our results suggest that PCVs confer reasonable protection, against acquisition of 
pneumococcal carriage of the seven studies serotypes, for several years after vaccination, 
albeit with differences across serotypes.  
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MAIN TEXT  
 
Introduction  
 
Pneumococcal conjugate vaccines (PCVs) reduce disease largely through their impact on 
nasopharyngeal (NP) carriage acquisition of Streptococcus pneumoniae (the 
pneumococcus), a precondition for developing any form of pneumococcal disease [1]. The 
effect of PCV on carriage also drives the herd immunity effect of the vaccine in routine 
immunization, through a reduction in the transmission of vaccine serotypes (VT) in the 
community [2]. Recently, emphasis has been put on the importance of carriage as a proxy 
measure for PCV impact assessments, and for using carriage as an additional and essential 
biomarker in the licensure pathway of new pneumococcal vaccines [3, 4].  
 
A recent systematic review of the direct impact of PCVs on dosing schedules [5] showed 
consistent reductions in carriage of the serotypes targeted by the vaccine, including a few 
years after vaccination, with evidence favouring 3-dose schedules over fewer doses. 
However, systematic estimates of the efficacy of PCVs against carriage and the duration of 
protection conferred are lacking.  Such estimates will help improve predictions about the 
likely impact of introducing the vaccine in routine immunization under different 
epidemiological scenarios. Estimates of the rate of waning efficacy are important not only to 
quantify the level of individual protection over time, but also the degree with which 
vaccinated children contribute to reducing community transmission as they age. Efficacy 
against carriage estimates also provide an essential benchmark against which new vaccines 
and vaccines under development can be evaluated, alongside other markers used in 
licensure [3]. 
 
We here aimed to studiedy the vaccine efficacy and duration of protection of pneumococcal 
vaccines against carriage, through meta-regression models. 
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Methods 
 
Search strategy 
We identified intervention studies reported by Fleming-Dutra et al. [5] in a recent systematic 
review of PCV vaccination schedules, which was based on data published between 1994 
and September 2010, with post-hoc supplementation of studies published from 2011. We 
searched for any additional study published between 2011 and 31 May 2014 using a similar 
strategy as in [5], using EMBASE and MEDLINE databases. Details are provided in 
Appendix 1. 
 
Inclusion criteria 
We considered the following initial criteria for inclusion: (i) intervention studies (ii) providing 
nasopharyngeal carriage estimates in vaccinated and unvaccinated children, (iii) with 
children vaccinated as per routine schedule, including three primary doses (‘3+0’ schedule) 
or at least two primary doses with a booster dose (‘2+1’ and ‘3+1’ schedules). We further 
restricted our analysis to studies of either 7-valent, 10-valent or 13-valent licensed vaccines 
(PCV7, PCV10 and PCV13) or unlicensed vaccines (e.g. PCV9 and PCV11) linked to similar 
carrier proteins as licensed vaccines, including the Corynebacterium diphtheria toxin mutant 
197 (CRM197), meningococcal outer membrane protein complex (OMPC) or the non-
typeable Haemophilus Influenzae derived protein D (NTHi). Studies based on vaccines 
conjugated to other proteins or for which immunological equivalence is unclear (such as 
tetra- and penta-valent vaccines [6-8]) were not included.  
Given that PCVs are not known to affect carriage clearance [9, 10], that the average duration 
of vaccine serotype (VT) carriage in infants and young children is somewhere around two 
months, but may vary by setting and serotype [11-14], and that 2-4 weeks are required for 
the antibody response to peak after vaccination, we excluded any data collected earlier than 
four months after complete vaccination, when the prevalence and serotype distribution was 
considered non-stationary, as detailed elsewhere [15, 16].  
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Data extraction  
All but four studies were PCV7 trials, with three other trials based on PCV9 and one on 
PCV10. We extracted data on the group of PCV7 serotypes, as well as each individual 
PCV7 serotype (4, 6B, 9V, 14, 18C, 19F, 23F). We also extracted data on serotypes 6A and 
19A, two common serotypes that share immunological traits 6B and 19F, but are not 
included in PCV7, PCV9 or PCV10, to explore possible cross-reactive protective efficacy. 
Other potential cross-reactive serotypes were not studied, due to limited data. 
 
Analysis  
We defined the vaccine efficacy against carriage acquisition (VEC) as the relative reduction 
in the rate of carriage acquisition among vaccinated compared to unvaccinated children. 
Although acquisition events cannot directly be observed, it is possible to obtain a robust 
estimate of VEC from cross sectional data based on 1 - OR (odds ratio), under general 
assumptions, with the OR defined as the odds of vaccination among the (group of) VT 
serotype(s) (henceforth, the ‘target’ group) to the odds of vaccination among those not 
carrying any VT (henceforth the ‘reference’ group) [15-17]. Hence, in calculating the VEC for 
each individual PCV7 serotype, we included in the target group all vaccinated and 
unvaccinated carriers of the particular serotype and in the reference group all non-vaccine 
serotype (NVT) carriers and non-carriers.  Other VT were excluded from the serotype-
specific analysis to account for vaccine-induced within-host changes in the pneumococcal 
flora, as explained elsewhere [15]. We also excluded all VT serotypes from the analysis of 
VEC against 6A and 19A.  Similarly, in trials based on vaccines with higher valency than 
PCV7 data on the additional VT serotypes were excluded.  Further details about the 
methods and assumptions underpinning the estimation of VEC from cross-sectional data are 
described elsewhere [15-17].    
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We explored whether the proportion of carried VT serotypes out of all VT serotypes differed 
between studies, based on data in unvaccinated children,  and used I2 values to quantify 
heterogeneity [18]. 
 
We used a Bayesian logistic meta-regression model to estimate the aggregate and serotype-
specific VEC and its waning. In the model, for each study i , 
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, where ViP R and ViP T are the proportion of vaccinated individuals in the reference and target 
groups respectively, i  is the study-specific natural logarithm of the OR and 1 represents 
the coefficient by which the log(OR) changes for each increase in the natural logarithm of 
time t  since the peak VEC (i.e. 4 months after vaccination), such that 
i 1 *log(OR) log( )i it   , with time in months.  
 
We used a random effect model taking the between-study heterogeneity into account by 
assuming that i  were independent and sampled from a normal distribution centred around 
the mean log(OR) of carriage (  ) with a precision , such that ~ ( , )i N    and 
21/  , 
where 
2  is the between-study variance. A fixed effect was assumed for 1 . 
 
The VEC at time t  can therefore be expressed as follows: 
 
1 ( * )tVEc e t    
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We assigned uniform priors to   (unif (-10; 10)),   (unif (-10, 0)),   (unif (0,10)) and 1  
(unif (0,10)).  The time coefficient 1  was constrained to positive values, with the assumption 
that the efficacy should be declining. 
 
Some studies provided more than one estimate. However, we did not adjust for the lack of 
independence due to the limited number of estimates from each study..  
 
We explored the impact of schedule (booster (3+1 or 2+1) vs. non-booster (3+0)) by 
including schedule as a covariate in a multivariable model, and assigned a normal 
uninformed prior to its coefficient ( 2 ~N(0,103)). We used and interaction term between 
schedule and time to look for a difference in the waning by schedule, with a normal 
uninformed prior on the interaction coefficient ( 3 ~N(0,103)).  Studies in which a 23-valent 
polysaccharide vaccine (PPV23) booster dose was provided after a primary schedule (as in 
[19, 20]) were considered part of the 3+0 group, given the lack of effect of PPV23 on 
carriage [19].  
 
Finally, we conducted sensitivity analyses to explore the impact on our pooled VEC 
estimates of omitting any one study.  We also analysed two additional models of waning 
VEC, including a model where time was included as a linear covariate  and another model 
with an asymptotic function in which the VEC of carriage approaches zero as time 
approaches infinity.  Models were compared using the Deviance Information Criterion (DIC), 
a likelihood-based model fitting statistic for Bayesian models similar to the frequentist Akaike 
Information Criterion [21]. Further details are presented in Appendix 2.   
 
Posterior distributions were obtained through a Markov Chain Monte Carlo (MCMC) Gibbs 
sampling algorithm based on 2 chains of 100,000 iterations running in parallel, after a burn-
in of 5,000 iterations.  The model was implemented in R using the jags package [22]. 
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Results  
 
Characteristics of the studies included 
Of the eighteen intervention studies identified in [5], three were based on non-equivalent 
vaccines [6-8, 23] and one provided carriage data three months after the last dose [24], 
hence we ended up with thirteen studies. We identified two additional studies through our 
literature review, including a PCV7 trial with data six months after a 3+1 schedule[25], and 
another PCV10 trial with data collected in the first [26] as well the second year [27] after 
vaccination. Supplementary Figure S1 (Appendix 1) shows the results of the literature 
search.  Our analysis therefore included 15 individual publications [7, 10, 19, 20, 26-36] 
providing estimates from 22 different surveys, spanning from 5 months to 64 months after 
vaccination, and including 7,485 samples from vaccinated children, and 6,813 from 
unvaccinated children. All but four studies were based on PCV7. Three were PCV9 trials [29, 
32, 37] and one was a PCV10 trial [26, 27]. We were unable to restrict the latter to PCV7 
serotypes only (as all data for PCV10 serotype were aggregated), and we explored the 
sensitivity of our model output to including (or not) data from that study. Nine data points 
were from surveys after booster vaccination (Table 1). Two studies [10, 33] were nested 
within a cluster randomized trial. The clustering was not adjusted for, and we explored the 
impact of those study estimates in the sensitivity analysis (see below). Serotype-specific 
data were obtained for 10 studies (7 PCV7 and 3 PCV9 studies), with 14 data points [10, 20, 
25, 28, 29, 31-35]. 
 
Vaccine efficacy against carriage and its waning 
We estimated a peak VEC (i.e. 4 months after complete vaccination) of 62% (95%CrI 52 – 
72%) against all VT serotypes, decreasing to 57% (95%CrI 50 – 65%) six months after 
vaccination, when the number of data points in the model is the highest, and 42% (95%CrI 
19 – 54%) five years after vaccination (Figure 1, Table 2).  
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There was no evidence of a confounding effect of schedule on VEC (with the coefficient β2 
centred around zero (-0.03 (95%CrI -0.32; 0.63)) or that the waning rate differed by schedule 
(interaction term β3 0.01 (95%CrI -0.24; 0.13)). However, taken individually the median 
waning coefficient 1  was smaller (i.e. ‘flatter’ slope) after a booster than after a 3+0 
schedule (Figure 2 and Table 2). 
 
The serotype distribution among the unvaccinated children was fairly stable across studies 
(Figure 3), with little or moderate statistical heterogeneity in the distribution of serotypes 
among PCV7 positive samples (serotype-specific I2 values of heterogeneity ranging from 0% 
to 60%). Serotypes 6B, 23F and 19F were the VT serotypes most commonly 
foundcirculating VT serotypes, contributing to 26%, 22%, 28% respectively of the isolated 
PCV7 serotypes overall among unvaccinated children. Serotype 14 was found in 11% and 
serotypes 4, 9V and 18C in 3%, 6% and 3% of PCV7 samples. Serotype 6A was found in 
about 9% of unvaccinated children, a little higher than the prevalence of 6B (8%, p=0.07), 
while the prevalence of 19A was low, at about 4% overall. 
 
Efficacy estimates differed across PCV7 serotypes. Six months after vaccination the highest 
VEC was measured for serotypes 4 (80%) and 9V (79%), and the lowest for 19F (38%) 
(Figure 4 and Table 2). 
 
The decline in the efficacy over time varied by serotype (Table 2), with the slowest decline 
for serotypes 23F and 19F (median 1 0.09) and more rapid declines for rarer serotypes, 
although credible intervals overlapped for all serotypes (Table 1). 
 
Thirteen study estimates contributed to the analysis of the pooled VEC against 19A, and 
fourteen to that of 6A. We found no evidence of cross protection conferred by the vaccine 
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against serotype 19A (Table 2), but found good evidence of protection against 6A, with a 
peak VEC of 48% (95%CrI 18% – 72%), decreasing to zero within five years post vaccination 
(Table 2, Figure 4).  
 
Sensitivity analysis 
Our sensitivity analysis showed no significant impact of any study estimate on the 
coefficients. Estimates were similar after excluding the cluster randomized trial [10, 33], with 
a VEC of 62% (51 – 73%) at 4 months, decreasing to 40% (12 – 54%) at 5 years. Excluding 
the two estimates from Cheung et al. in the Gambia [29], which together accounted for about 
28% of all children included in the analysis, did not affect model estimates (VEC of 62% (50 – 
74%) at 4 months and 39% (12 – 54%) at 5 years). Finally, overall and booster schedule 
VEC estimates and respective model coefficients were similar with and without data from the 
PCV10 trial [26, 27]. 
 
We explored two other models of waning, in addition to the main model (Appendix 2). In all 
three models there was good evidence of protective efficacy in the first few years after 
vaccination. A similar DIC was obtained for all three models estimating the aggregate VEC, 
as well as for serotype-specific models, except for serotypes 14 and 19F for which the model 
with the asymptotic time function was outperformed by the other two. Further information can 
be found in Appendix 2.   
 
Discussion 
 
We computed pooled aggregate and PCV7 serotype-specific vaccine efficacy against 
nasopharyngeal acquisition and its waning based on a meta-regression model of cross-
sectional data.  Our results suggest that PCVs confers reasonable protection against 
acquisition of pneumococcal carriage of the seven studies serotypes, for several years after 
vaccination, albeit with differences across serotypes. 
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Previous studies have explored PCV efficacy against carriage [16] and compared schedules 
[5], however, a pooled estimate was not previously calculated. We found that the distribution 
of VT serotypes was relatively stable across settings, making the pooling of aggregate 
estimates possible despite differences in the efficacy against individual serotypes.  
Three serotypes (6B, 19F and 23F) accounted for about 75% of all PCV7 serotypes, but 
efficacy for each of those differed, with high efficacy against 6B and a weaker anti-19F 
efficacy. A possible reason for this divergence is the difference in the amount of antibody 
required for protection as well as differences in the vaccine-induced opsonophagocytic 
activity (i.e. the ingestion of pathogens by phagocytes), despite similar antibody geometric 
mean concentrations (GMCs) following PCV7 vaccination [30, 38]. Interestingly, a recent 
study in the UK on the vaccine effectiveness and immune correlates of protection against 
IPD [39] showed that much less antibody is required for 6B and 23F protection than for 19F 
protection.  The polysaccharide capsule of 19F is more resistant to complement deposition 
than 6B and requires higher levels of antibodies for opsonophagocytosis [38]. However, 
although trials [37, 40] have shown persistence of serum antibodies several years after 
vaccination, the exact mechanism underlying the protection against acquisition of carriage is 
stillremains unclear.  andSuch mechanisms may involve memory B cells residing in the 
nasopharyngeal compartment responding to carriage and secreting local IgG or IgA rather 
than pre-existing circulating serum IgG, with serological markers thus incompletely capturing 
the mucosal response.  
While natural immunity to colonization in infancy is poor, conjugate vaccines stimulate B-cell 
responses and the generation of memory B-cells [41], which can be naturally boosted.  If 
boosting does contribute to maintaining a protective efficacy then one might expect efficacy 
to wane faster for rarer serotypes and slower for the more prevalent ones. Our results 
support such a hypothesis to some extent, showing a slower VEC decline for the most 
prevalent serotypes. This would also mean that efficacy may wane more rapidly after routine 
implementation of the vaccine than in trial conditions. 
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We found evidence of cross-protective efficacy against 6A acquisition, but not 19A, based on 
data from PCV7 and PCV9 trials. Such evidence is supported by trials and observational 
studies showing an impact of PCV7 on 6A disease [42], and unclear evidence on 19A 
disease [43]. Although three doses of PCV7 increase 6A and 19A antibody concentrations 
above putative protective thresholds, evidence shows that the vaccine elicits functional 
antibodies (i.e. antibodies inducing opsonophagocytosis) against 6A, but not 19A [44].  
 
The direct impact on disease is not solely conditioned on the VEC, but also on the efficacy of 
the vaccine against progressing to disease as a result of carriage [1]. This explains the 
higher efficacy of PCV against invasive disease, at around 80% [1, 3, 39]1 [1, 3, 39, 45]. In 
contrast, the efficacy on disease progression against mucosal forms of disease, such as 
acute otitis media (AOM), is small with most of the disease impact predicted by VEC only [1, 
3, 45] [1, 3] . Interestingly, the efficacy against pneumococcal AOM among Finnish children 
enrolled in a large PCV7 trial [30] was 62% (48 – 72%) in the year following the booster 
dose, and serotype-specific efficacies were lowest for serotype 19F, at about 37%, and high 
for 6B (79%) 4 (75%,) and 9V (82%). Those estimates are similar to our aggregate and 
serotype-specific efficacies, adding to the evidence that VEC is a close measure of the 
efficacy against AOM.  
 
An important question is the applicability of our results to 10- and 13-valent vaccines, given 
that many countries have introduced – or are planning to do so – those vaccines into their 
routine vaccination programmes.  Data on immunological correlates of protection from trials 
suggest non–inferiority of PCV13 and PCV10 to PCV7 in the response against the serotypes 
included in PCV7 [44, 46]. However, a recent study comparing IgG concentration and 
functional antibodies in PCV7 and PCV13 vaccinated Navajo and White Mountains Apache 
children in the US [47] found higher functional antibody activity against 19F after PCV13 
vaccination, compared to PCV7, which and lower 6B functional antibody activity. The 
increased activity against 19F is explained by the inclusion of 19A in PCV13 and the 
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additional activity of anti-19A antibodies against 19F. The  This could translate in differences in 
aggregate VEC, particularly since 19F is amongst the most prevalent serotypes [48].  
 
The estimation of the efficacy against carriage acquisition from cross sectional data relies on 
several assumptions, the most important being that of stationarity – i.e. that the relationship 
between carriage incidence and carriage prevalence is stable [15, 16]. Vaccination will 
introduce some temporary disturbance in the carriage rates of different serotypes, with the 
average prevalence estimates stabilising after some time [49]. Auranen et al. [17] suggest 
that stationary levels should not be considered before at least twice the duration of carriage 
since vaccination. We included studies from four months after vaccination to account for this, 
which we considered this to be a good trade-off between ensuring steady-state carriage 
levels and avoiding peak estimates to be affected by waning VEC.   
 
The assumption that PCV do not affect clearance is based on limited evidence [9, 10]. 
Similarly, studies have suggested that the vaccine may also impact carriage density [10]. In 
both scenarios (reduced duration and reduced density), VEC could represent a combined 
efficacy estimate against acquisition and transmission under the assumption that a reduction 
in duration of carriage and/or carriage density is associated with both a reduction in the 
likelihood of detection and of transmission, as discussed elsewhere [15, 16]. 
 
Our study has a number of additional limitations.   
First, our analysis was limited by the number of data points, with wider uncertainty as time 
since vaccination increases and the smaller study sizes for serotype specific analyses, with 
substantial uncertainty around model estimates for the least prevalent serotypes. The small 
number of data points in each schedule subgroup may have limited our ability to detect any 
difference between schedules  
Second, studies were based on the identification of the dominant serotype in single colonies 
and multiple colonization was not taken into account. If the prevalence of multiple 
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colonization is low and if there are no differences in the propensity of detecting one serotype 
over another, VEC estimates based on single colonization would nonetheless adequately 
capture VEC [15]. 
 
There are several other factors related to vaccine schedules and delivery that may impact on 
VEC (and on the heterogeneity between studies) which we were unable to explore, including 
the timing and spacing of doses  and the co-administration of PCV with different childhood 
vaccines [46]. For example, a recent systematic review of the impact of PCV vaccination 
schedules on immunological responses [46] suggests that immune responses to serotype 14 
may be influenced by co-administration of PCV with DTP vaccines, with significantly higher 
GMCs observed with acellular pertussis compared to the whole cell pertussis vaccine. 
 
In addition, although the description of the swabbing and sample processing techniques 
used in the studies included – although sometimes limited – seem to conform to WHO 
guidelines [50], we cannot rule out that some of the between-study heterogeneity may be 
due to differences in such techniques.  
 
Finally, further research to obtain more precise estimates of VEC after non-complete 
schedules, particularly single catch-up doses, is warranted. This is particularly relevant in the 
context of PCV roll out in low-income settings, as some countries may opt for catch-up 
campaigns at the introduction of the vaccine. 
 
In conclusion, through this study we provide consistent evidence for a lasting efficacy of PCV 
in children during the first few years after completion of vaccination, although with 
differences in efficacy and duration of protection between serotypes.  
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Table 1: Studies included in the analysis 
Study Country 
PCV 
valency 
Schedule 
NP swab collection: time 
since last PCV dose 
Total number of 
children included 
PCV7 VEC (95CrI) at each sample 
collection in the survey  
Cheung et al. (2009) [29] The Gambia PCV9 3+0 6 months, 16 months 2092,1847 58% (49%;65%), 54% (44%;62%) 
Dagan et al. (2012) [28] Israel PCV7 3+0 6 months 499 51% (24%;68%) 
Kilpi et al. (2001) [25] Finland PCV7 3+1 6 months 2403 41% (23%;54%) 
Lakshman et al. (2003) [20] UK PCV7 3+1PPV23 29 months, 36 months 276, 331 29% (-49%;66%), 5% (-59%;43%) 
Madhi et al. (2007) [31] South Africa PCV9 3+0 64 months 271 36% (-25%;68%) 
Mbelle et al. (1999) [32] South Africa PCV9 3+0 6 months 481 62% (43%;76%) 
Millar et al. (2006) [33] USA PCV7 3+1 27 months 197 45% (-2%;70%) 
Obaro et al. (2000) [7] The Gambia PCV7 3+0 5 months 434 65% (40%;79%) 
O’Brien et al. (2007) [10] USA PCV7 3+0, 3+1 7.5 months (3+0), 7.5 months (3+1) 458, 469 44% (11%;65%), (51% (23%;69%) 
Palmu et al. (2002) [34] Finland PCV7 3+1 46 months 352 46% (-16%;76%) 
Prymula et al. (2011) [26] Czech Republic PCV10*$ 3+0, 3+1 8.5 months (3+0) , 535,  59% (27%;79%) 
    7 months (3+1), 12 months (3+1) 538, 541 39% (-5%;65%), 52% (12%;75%) 
 
Prymula et al. (2013) [27] Czech Republic PCV10*$ 3+1 19 months 316 62% (19%;83%) 
Russell et al. (2010) [19] Fiji PCV7 3+1PPV23 6 months, 9 months 248, 269 83% (53%;95%), 70% (31%;79%) 
van Gils et al. (2009) [35] The Netherlands PCV7 2+1 7 months, 13 months 646, 654 70% (56%;79%), 70% (57%;80%) 
Yeh et al. (2003) [36] USA PCV7 3+0 6 months 69 -4% (-373%;74%) 
*In this trial two PCV10 arms were included, one receiving pre-vaccination paracetamol prophylaxis and one without prophylaxis. Only data from the latter and 
the placebo group were included.   $Serotype –specific data were not available and VEC in this trial is against all PCV10 serotypes, not PCV7 serotypes as in 
other studies included.
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Table 2: Aggregate and serotype-specific vaccine efficacy at different time points post vaccination, and model coefficient estimates  
 VEC (95%CrI) at several time points after vaccination  Coefficient estimates (95%CrI) 
PCV7 serotypes Peak (4 months) 6 months 2 years 5 years  µ 1β  (waning) 
4 88% (62%;98%) 80% (54%;92%) 50% (-50%;78%) 18% (-328%;74%)  -2.11 (-3.75; -0.97) 0.46 (0.04; 1.21) 
6B 77% (64%;89%) 72% (62%;83%) 62% (41%;72%) 54% (13%;71%)  -1.48 (-2.20; -1.03) 0.17 (0.01; 0.48) 
9V 89% (71%;97%) 79% 64%;90%) 39% (-31%;69%) -9% (-295%;62%)  -2.17 (-3.43; -1.24) 0.56 (0.11; 1.21) 
14 64% (44%;81%) 57% (40%;71%) 40% (6%;58%) 29% (-44%;56%)  -1.01 (-1.65; -0.57) 0.16 (0.09; 0.47) 
18C 59% (25%;82%) 52% (19%;73%) 34% (-14%;60%) 22% (-75%;58%)  -0.90 (-1.74; -0.29) 0.15 (0.01; 0.50) 
19F 44% (28%;62%) 38% (24%;51%) 25% (3%;39%) 17% (-25%;37%)  -0.58 (-0.96; -0.33) 0.09 (0.01; 0.27) 
23F 64% (49%;81%) 60% (46%;73%) 51% (25%;64%) 47% (3%;62%)  -1.02 (-1.64; -0.67) 0.09 (0.00; 0.36) 
Cross reactive serotypes        
6A 48% (18%%;72%) 39% (11%;58%) 16% (-33%%;41%) 0% (-95%;38%)  -0.65 (-1.28; -0.19) 0.15 (0.01; 0.43) 
19A 30% (-2%;70%) 11% (-14%;48%) 0 0  -0.36 (-1.21; 0.02) 0.22 (0.03; 0.58) 
All PCV7 serotypes        
All schedules  62% (52%;72%) 57% (50%;65%) 47% (35%;56%) 42% (19%;54%)  -0.97 (-1.30;-0.72) 0.11 (0.01; 0.25) 
Booster schedule  63% (49%;80%) 60% (47%;73%) 52% (30%;63%) 47% (6%;62%)  -1.00 (-1.64; -0.68) 0.08 (0.00; 0.36) 
Primary dose schedule  66% (54%;77%) 59% (50%;67%) 42% (23%;54%) 31% (-7%;51%)  -1.10 (-1.49; -0.78) 0.18 (0.01; 0.37) 
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Figure 1: Plot of the model of VEC over time and its 50% and 95% credible intervals, 
together with the individual study estimates 
 
Legend: The plain line shows the model median, the dark grey shaded area the 50% 
credible interval (CrI) and the light grey shaded area the 95% CrI. The circles represent the 
point estimates of each individual study, with the size of the circle proportional to the study 
size, and the dotted vertical lines show the 95% confidence interval for each study 
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Figure 2: The vaccine efficacy and its waning, for schedules with a booster (right panel) and 
without a booster dose (left panel). 
 
 
 
Legend: Left panel: model for 3+0 schedules. Left panel: 2+1 or 3+1 schedules.  
The plain dark regression line shows the model median, the grey shaded area the 95% 
credible interval (CrI) and the dotted lines the upper and lower bounds of the 95%CrI. The 
circles represent the point estimates of each individual study, with the size of the circle 
proportional to the study size, and the dotted vertical lines show the 95% confidence interval. 
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Figure 3: Distribution of the serotypes contained in PCV7, in each of the studies included in 
the serotype-specific model of vaccine efficacy 
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Figure 4: Serotype-specific models of vaccine efficacy against carriage, for each of the PCV7 serotypes as well as for serotype 6A 
 
Legend: The black plain lines represent the model median and the grey shaded areas the model 95% credible interval. The 
squares and vertical dotted bars represent the study-specific point VEC estimates and their 95% confidence interval.
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Appendix 1: Literature search to complement the existing systematic review  
Search strategy 
We searched for any additional study published between 2011 and 31 May 2014 using 
MEDLINE and EMBASE databases, and the same search strategy as in [5], but restricted to 
nasopharyngeal carriage as outcome. 
 
We used the following keywords [all fields] : 
Search #1: pathogen 
“Streptococcus pneumoniae” OR (“Diplococcus” AND “pneumoniae”) OR (“micrococcus” 
AND “pneumoniae”) OR “Pneumococcus” OR “pneumococcal” OR “s.pneumoniae” OR 
“pneumococci” OR “streptococcus” OR “streptococcal” OR “Pneumococc” 
Search #2: outcome 
(“Nasopharyngeal” AND “carriage”) OR (“Nasopharyngeal” AND “colonization”) OR 
(“Nasopharyngeal” AND “colonisation”) 
Search #3: vaccine 
“Vaccine” OR “vaccines” OR “vaccination” OR “vaccinated” OR “immunization” OR 
“immunisation” OR “immunized” OR “immunised” OR “PCV” OR “Prevenar” OR “PCV7” OR 
“PCV-7” OR “PNCRM7” OR “PNCRM-7” OR “PCV10” OR “PCV-10” OR ”PCV9” OR “PCV-9” 
OR “PCV11” OR “PCV-11”. 
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Results 
Combining those three searches yielded 468 citations. After automatic and manual de-
duplication, we ended up with 208 citations to screen.  
Of those, 179 were excluded based on the title or the abstract. The full text of 29 references 
were screened. Of those, three were from trials meeting our inclusion criteria, including a 
PCV7 trial from Israel [28] and a PCV10 trial from the Czech Republic, with two different 
publications [26, 27] (Figure S1 below). Additionally, we also retreived data from a large 
Finnish trial presented at a conference in 2001 [25], and used illustratively by Auranen et 
al.[15]  
 
Supplementary Figure S1: Flow diagram of the literature search 
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Appendix 2: Comparing models of waning VEC 
 
Three models of waning VEC were considered.  
 
For each study i , 
 
Vi
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Vi
1 *
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log( ) log( )
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i i i
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
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, where ViP R and ViP T are the proportion of vaccinated individuals in the reference and target 
groups respectively, i  is the study-specific natural logarithm of the OR  
 
We used a random effect model taking the between-study heterogeneity into account by 
assuming that i  were independent and sampled from a normal distribution centred around 
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the mean log(OR) of carriage (  ) with a precision , such that ~ ( , )i N    and 
21/  , 
where 
2  is the between-study variance. A fixed effect was assumed for 1 . 
 
Therefore, the vaccine efficacy at time t (VECt) is as follows; 
 
*1 ( )tVEc e t       # In model 1   
( )1 ttVEc e         # In model 2 
( )1
t
tVEc e        # In model 3 
 
We used the same priors in all three models. 
 
The models outputs were compared visually (Figure S1) as well as through the Deviance 
Information Criterion (DIC), with the smallest DIC suggesting the best model fit.  
 
In the models of vaccine efficacy against carriage acquisition of all VT serotypes, the DIC 
was the same at 307.7, 307.4 and 307.0 for models 1, 2 and 3 respectively.  Differences in 
DIC smaller than 5 are not considered meaningful in random effects meta-regression 
models. 
 
The DIC for the modelling of each individual serotype and each model considered are shown 
in Table S1. 
 
The smallest DIC values were consistently seen for model 1 (the main model presented) – 
with the exception of serotype 9V -, but the difference in DIC values between models was 
not considered significant, except for 19F for which model 3 was outperformed by the two 
other models.  
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Supplementary Figure S2: Model 1 (left panel), model 2 (middle panel) and model 3 (right panel) 
 
Legend: Left panel: model 1. Middle panel: Model 2. Right panel: Model 3. 
 The plain line shows the model median, the dark grey shaded area the 50% credible interval (CrI) and the light grey shaded area the 95% CrI. The circles 
represent the point estimates of each individual study, with the size of the circle proportional to the study size, and the dotted vertical lines show the 95% 
confidence interval for each study 
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Supplementary Table S1: Deviance Information Criterion (DIC) values for ST-specific 
models, comparing each of the three models considered 
 Deviance Information Criterion for each model 
Serotype MODEL 1 MODEL 2 MODEL3 
4 116.7 117.0 119.0 
6B 193.2 193.2 193.5 
9V 142.9 142.0 143.5 
14 174.4 175.3 178.4 
18C 151.9 151.9 153.6 
19F 193.4 193.4 199.5 
23F 192.8 193.3 193.7 
6A 192.7 192.8 193.5 
 
Hence, model 1 was presented as the main model in this paper based on a priori 
assumptions about the waning of vaccine efficacy, rather than on strong statistical grounds 
when comparing model 1 to the two other models. 
